title: Long-term follow-up of 14 patients with philadelphia chromosome-positive acute lymphoblastic leukemia following autologous bone marrow transplantation in first complete remission.
abstract: We describe the clinical outcome of autologous bone marrow transplantation (ABMT) for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL). Between 1985 and 2000, 14 patients in first complete remission underwent transplantation. In all cases, harvested marrow was purged with a cocktail of complement and monoclonal antibodies to common acute lymphoblastic leukemia antigen (CALLA). Eight patients died following BMT: 2 patients from interstitial pneumonia and 6 from disease recurrence. For the 6 surviving patients in continuous remission, the median follow-up period was 96 months. The probability of disease-free survival and the rate of relapse at 5 years were 41.7% and 51.4%, respectively. Minimal residual disease (MRD) was assayed quantitatively with patient-specific D-JH probes in 6 of 14 cases. A higher residual tumor burden at marrow harvest was associated with subsequent relapse. Efforts to reduce the MRD burden before harvesting stem cells should improve the clinical outcome of ABMT.
authors.affiliation: Department of Hematology, Fujita Health University Hospital, Toyoake, Japan.
authors.forename: Shuichi
authors.initials: S
authors.lastname: Mizuta
authors.forename: Akio
authors.initials: A
authors.lastname: Kohno
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Morishita
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Atsuta
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sao
authors.forename: Koichi
authors.initials: K
authors.lastname: Miyamura
authors.forename: Hisashi
authors.initials: H
authors.lastname: Sakamaki
authors.forename: Ryuzo
authors.initials: R
authors.lastname: Ueda
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Morishima
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality / Q000628:therapy*; D012008:Recurrence; D012074:Remission Induction; D014182:Transplantation, Autologous